The overall goal of this research project is to develop new types of agents for the treatment of HIV infections in humans. The general approach that we have selected is to interfere with the biosynthesis of glycoproteins, specifically gp120. We have chosen to inhibit certain enzymes involved in the oligosaccharide processing pathway of this glycoprotein. Glycoprotein gp120 has been shown to have mainly oligosaccharides of the complex type (biantennary) and high-mannose-type. Our initial target enzymes are in the pathways leading to the complex-type species of oligosaccharides.
The specific aims of this proposal are: 1. To design inhibitors of the following enzymes involved in the processing of linked oligosaccharides: a. alpha-Mannosidases I and II. b. N-Acetyilglucosaminyltransferases I and II. c. Galactosyltransferase. 2. To develop synthetic routes for the preparation of these inhibitors. 3. To evaluate the biologic activity of the new agents against HIV in cell culture. 4. To further evaluate promising compounds for their effects on the glycosylation pathway. 5. To assess potential toxicity of promising compounds. 6. To evaluate promising compounds in combination with other useful agents such as AZT against HIV in cell culture. Promising combinations would be assessed for potential toxicity. The types of compounds that we will be making are oligosaccharides, oligosaccharide analogs, and O- glycosylnucleosides. Standard organic synthetic chemistry will be used to prepared the various target compounds.

Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Comber, R N; Friedrich, J D; Dunshee, D A et al. (1994) Alpha-(1-->2)-, and alpha-(1-->3)-, and alpha-(1-->6)-linked thioglycosidic disaccharides: syntheses and anti-HIV testing of thiokojibiose octaacetate, thionigerose, and thioisomaltose. Carbohydr Res 262:245-55
Bray, M; Prasad, S; Dubay, J W et al. (1994) A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A 91:1256-60
Srinivas, S K; Srinivas, R V; Anantharamaiah, G M et al. (1993) Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins. J Biol Chem 268:22895-9
Salzwedel, K; Johnston, P B; Roberts, S J et al. (1993) Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol 67:5279-88
Hallenberger, S; Tucker, S P; Owens, R J et al. (1993) Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. Virology 193:510-4
Johnston, P B; Dubay, J W; Hunter, E (1993) Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol 67:3077-86
Cretton, E M; Xie, M Y; Goudgaon, N M et al. (1992) Catabolic disposition of 3'-azido-2',3'-dideoxyuridine in hepatocytes with evidence of azido reduction being a general catabolic pathway of 3'-azido-2',3'-dideoxynucleosides. Biochem Pharmacol 44:973-80
Dubay, J W; Roberts, S J; Hahn, B H et al. (1992) Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol 66:6616-25
Dubay, J W; Roberts, S J; Brody, B et al. (1992) Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol 66:4748-56
Weidner, D A; Bridges, E G; Cretton, E M et al. (1992) Comparative effects of 3'-azido-3'-deoxythymidine and its metabolite 3'-amino-3'-deoxythymidine on hemoglobin synthesis in K-562 human leukemia cells. Mol Pharmacol 41:252-8

Showing the most recent 10 out of 33 publications